You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 10,544,200


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,544,200
Title:Glycoprotein hormone long-acting superagonists
Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.
Inventor(s): Szkudlinski; Mariusz (Rockville, MD), Weintraub; Bruce D. (Rockville, MD)
Assignee: TROPHOGEN, INC. (Rockville, MD)
Application Number:15/034,670
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Patent Landscape and Claims Analysis: A Comprehensive Guide

Introduction

The United States patent system is a complex and evolving field, particularly with the advent of new technologies and legislative changes. This article delves into the patent landscape, focusing on the claims and processes surrounding patents, using the context of the United States Patent 10,544,200 as a case study.

Overview of U.S. Patent Law

Patents are a form of intellectual property that grant inventors exclusive rights to their inventions for a limited period, typically 20 years from the filing date of the patent application[1].

What Are Patents?

Patents represent a "quid pro quo" where the inventor publicly discloses an invention in exchange for time-limited, exclusive rights to practice it. The U.S. Patent and Trademark Office (USPTO) is responsible for evaluating patent applications and granting patents on qualifying inventions[1].

The Leahy-Smith America Invents Act (AIA)

The AIA, enacted in 2011, is a significant milestone in U.S. patent law. It introduced several key changes, including the creation of the Patent Trial and Appeal Board (PTAB) and new types of administrative challenges to patent validity, such as Inter Partes Review (IPR) and Post-Grant Review (PGR)[1].

Role of PTAB

PTAB is a tribunal within the USPTO that hears challenges to the validity of patents. These challenges can be initiated by anyone and, if successful, can result in the cancellation of patent claims deemed invalid. This process is often faster and less expensive than judicial proceedings, making it a preferred route for accused patent infringers[1].

Patent Claims Analysis

Patent claims are the heart of a patent, defining the scope of the invention and the rights granted to the inventor. Here are some key aspects of patent claims analysis:

Importance of Claims

The business and legal value of a patent resides in its claims. With the increasing number of patent applications and claims, automated systems like the Patent Matrix software have been developed to facilitate the review of claims by importing, parsing, and compressing/expanding them[2].

Novelty and Nonobviousness Requirements

For a patent to be granted, the claimed invention must be novel and nonobvious. Novelty requires that the invention was not previously patented, described in a printed publication, or in public use before the effective filing date. Nonobviousness means that the invention must be significantly different from existing knowledge and not obvious to a person skilled in the art[1].

Use of AI in Patent Applications

The increasing use of AI tools in patent applications has introduced new complexities. If an AI tool is material to patentability, its use must be disclosed to the USPTO. This includes any contributions made by AI to the drafting of the patent application or claims, and practitioners must verify the accuracy of all documents prepared with AI assistance[3].

Case Study: United States Patent 10,544,200

While specific details of the United States Patent 10,544,200 are not provided here, we can apply the general principles discussed above to understand its claims and context.

Claim Construction

The claims of a patent like 10,544,200 would be subject to the same scrutiny as any other patent. This involves determining whether the claims are directed to eligible subject matter and whether they meet the novelty and nonobviousness requirements. The Alice/Mayo test would be applied to ensure that the claims have an "inventive concept" if they are directed to ineligible subject matter[1].

Potential Challenges

Given the PTAB's role, any patent, including 10,544,200, could face challenges through IPR or PGR. These proceedings allow third parties to challenge the validity of patent claims before the USPTO, potentially leading to the cancellation of claims if they are found invalid[1].

Economic and Litigation Aspects

Patent Values and Litigation

Research by the USPTO's Office of the Chief Economist has shown that patent values can be estimated based on renewal choices and citation dynamics. This research also highlights the importance of comprehensive datasets in studying patent litigation, which can include details on litigated patents, case types, and related case information[4].

Quality of Patents

The Government Accountability Office (GAO) has recommended that the USPTO more consistently define and articulate patent quality. This involves ensuring that examiners have sufficient time to perform thorough examinations, particularly in complex technology areas[5].

Current Debates and Reforms

The PTAB and the broader patent system are subject to ongoing debates and proposed reforms. Key issues include standing, burdens of proof, discretionary institution of IPRs, claim construction, and the role of the USPTO Director in reviewing PTAB decisions[1].

Key Takeaways

  • Patent Claims: The core of a patent, defining the scope and rights granted.
  • PTAB and AIA: Introduced new administrative challenges to patent validity, making the process faster and less expensive.
  • AI in Patents: Requires disclosure and verification of contributions to ensure accuracy.
  • Economic and Litigation Aspects: Patent values and litigation data are crucial for understanding the patent landscape.
  • Quality and Reforms: Ongoing efforts to define and improve patent quality and the efficiency of the patent system.

FAQs

What is the role of the Patent Trial and Appeal Board (PTAB)?

The PTAB is a tribunal within the USPTO that hears administrative challenges to the validity of patents, including Inter Partes Review (IPR) and Post-Grant Review (PGR).

How do AI tools impact patent applications?

AI tools must be disclosed if their use is material to patentability. Practitioners must verify the accuracy of all documents prepared with AI assistance to avoid introducing inaccurate statements.

What are the key requirements for patentability?

A claimed invention must be novel, nonobvious, and directed to eligible subject matter. It must also meet the "inventive concept" test if it is directed to ineligible subject matter.

Why is claim construction important?

Claim construction determines the scope of the invention and the rights granted to the inventor. It is crucial for understanding what is protected by the patent.

What are some current debates in the patent system?

Current debates include issues around standing, burdens of proof, discretionary institution of IPRs, claim construction, and the role of the USPTO Director in reviewing PTAB decisions.

How does the USPTO ensure patent quality?

The USPTO has increased the time available for certain art units to perform thorough examinations and has engaged external and internal stakeholders to improve the examination process.

Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," Updated May 28, 2024.
  2. Google Patents, "US20110138338A1 - Patent Claims Analysis System and Method."
  3. Buchanan Ingersoll & Rooney PC, "U.S. Patent Office Issues Additional Guidance on Use of AI Tools," April 15, 2024.
  4. USPTO, "Working papers and book chapters - USPTO."
  5. GAO, "Intellectual Property: Patent Office Should Define Quality, Reassess Processes," June 30, 2016.

More… ↓

⤷  Subscribe

Details for Patent 10,544,200

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 January 15, 1974 10,544,200 2033-11-05
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 December 27, 1984 10,544,200 2033-11-05
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 15, 1985 10,544,200 2033-11-05
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 16, 1990 10,544,200 2033-11-05
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 March 26, 1974 10,544,200 2033-11-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.